|Trade names Detrol, Detrusitol|
ATC code G04BD07 (WHO)
CAS ID 124937-51-5
Trade name Detrol, Detrusitol
Routes of administration By mouth
Molar mass 325.488 g/mol
|Pregnancy category AU: B3 US: C (Risk not ruled out)|
Tolterodine (trade names Detrol, Detrusitol) is an antimuscarinic drug that is used for symptomatic treatment of urinary incontinence.
- How to pronounce tolterodine detrol memorizing pharmacology flashcard
- Side effects of tolterodine
It is marketed by Pfizer in Canada and the United States by its brand name Detrol. In Egypt it is also found under the trade names Tolterodine by Sabaa and Incont L.A. by Adwia.
How to pronounce tolterodine detrol memorizing pharmacology flashcard
Detrusor overactivity (DO, contraction of the muscular bladder wall) is the most common form of urinary incontinence (UI) in older adults. It is characterized by uninhibited bladder contractions causing an uncontrollable urge to void. Urinary frequency, urge incontinence and nocturnal incontinence occur. Abnormal bladder contractions that coincide with the urge to void can be measured by urodynamic studies. Treatment is bladder retraining, pelvic floor therapy or with drugs that inhibit bladder contractions such as oxybutinin and tolterodine.
Tolterodine acts on M2 and M3 subtypes of muscarinic receptors whereas older antimuscarinic treatments for overactive bladder act more specifically on M3 receptors.
Tolterodine, although it acts on all types of receptors, has fewer side effects than oxybutynin (M3 and M1 selective, but more so in the parotid than in the bladder) as tolterodine targets the bladder more than other areas of the body. This means that less drug needs to be given daily (due to efficient targeting of the bladder) and so there are fewer side effects.
Side effects of tolterodine
Known side effects:
The following reactions have been reported in patients who have taken tolterodine since it has become available:
Contraindications: Not to be used in patients with myasthenia gravis and angle closure glaucoma.